nodes	percent_of_prediction	percent_of_DWPC	metapath
Repaglinide—PPARG—urinary bladder cancer	0.613	1	CbGaD
Repaglinide—SLCO1B1—Methotrexate—urinary bladder cancer	0.0361	0.187	CbGbCtD
Repaglinide—ALB—Fluorouracil—urinary bladder cancer	0.0358	0.186	CbGbCtD
Repaglinide—CYP3A4—Thiotepa—urinary bladder cancer	0.0345	0.179	CbGbCtD
Repaglinide—CYP2C8—Fluorouracil—urinary bladder cancer	0.0277	0.144	CbGbCtD
Repaglinide—CYP2C8—Etoposide—urinary bladder cancer	0.0231	0.12	CbGbCtD
Repaglinide—ALB—Methotrexate—urinary bladder cancer	0.0197	0.102	CbGbCtD
Repaglinide—ABCC8—penis—urinary bladder cancer	0.0113	0.264	CbGeAlD
Repaglinide—CYP3A4—Etoposide—urinary bladder cancer	0.00937	0.0486	CbGbCtD
Repaglinide—CYP3A4—Doxorubicin—urinary bladder cancer	0.00639	0.0332	CbGbCtD
Repaglinide—PPARG—Teniposide—Etoposide—urinary bladder cancer	0.00278	1	CbGdCrCtD
Repaglinide—ABCC8—prostate gland—urinary bladder cancer	0.00271	0.0631	CbGeAlD
Repaglinide—CYP3A4—urine—urinary bladder cancer	0.00257	0.0599	CbGeAlD
Repaglinide—ABCC8—seminal vesicle—urinary bladder cancer	0.00229	0.0534	CbGeAlD
Repaglinide—PPARG—prostate gland—urinary bladder cancer	0.00207	0.0482	CbGeAlD
Repaglinide—ABCC8—smooth muscle tissue—urinary bladder cancer	0.00192	0.0447	CbGeAlD
Repaglinide—ABCC8—renal system—urinary bladder cancer	0.00185	0.043	CbGeAlD
Repaglinide—SLCO1B1—renal system—urinary bladder cancer	0.00163	0.0381	CbGeAlD
Repaglinide—KCNJ11—female reproductive system—urinary bladder cancer	0.0016	0.0374	CbGeAlD
Repaglinide—PPARG—epithelium—urinary bladder cancer	0.00152	0.0354	CbGeAlD
Repaglinide—PPARG—smooth muscle tissue—urinary bladder cancer	0.00146	0.0341	CbGeAlD
Repaglinide—PPARG—renal system—urinary bladder cancer	0.00141	0.0328	CbGeAlD
Repaglinide—PPARG—urethra—urinary bladder cancer	0.00138	0.0323	CbGeAlD
Repaglinide—SLCO1B1—female reproductive system—urinary bladder cancer	0.00131	0.0305	CbGeAlD
Repaglinide—PPARG—female reproductive system—urinary bladder cancer	0.00113	0.0263	CbGeAlD
Repaglinide—PPARG—vagina—urinary bladder cancer	0.00102	0.0238	CbGeAlD
Repaglinide—KCNJ11—lymph node—urinary bladder cancer	0.000939	0.0219	CbGeAlD
Repaglinide—CYP2C8—renal system—urinary bladder cancer	0.000929	0.0216	CbGeAlD
Repaglinide—CYP2C8—female reproductive system—urinary bladder cancer	0.000744	0.0173	CbGeAlD
Repaglinide—CYP2C8—vagina—urinary bladder cancer	0.000673	0.0157	CbGeAlD
Repaglinide—PPARG—lymph node—urinary bladder cancer	0.00066	0.0154	CbGeAlD
Repaglinide—CYP3A4—renal system—urinary bladder cancer	0.000629	0.0147	CbGeAlD
Repaglinide—ALB—lymph node—urinary bladder cancer	0.000619	0.0144	CbGeAlD
Repaglinide—CYP3A4—female reproductive system—urinary bladder cancer	0.000504	0.0117	CbGeAlD
Repaglinide—Eye disorder—Cisplatin—urinary bladder cancer	0.000362	0.00353	CcSEcCtD
Repaglinide—Erythema—Gemcitabine—urinary bladder cancer	0.000362	0.00353	CcSEcCtD
Repaglinide—Alopecia—Fluorouracil—urinary bladder cancer	0.000361	0.00352	CcSEcCtD
Repaglinide—Cardiac disorder—Cisplatin—urinary bladder cancer	0.000359	0.0035	CcSEcCtD
Repaglinide—Erythema—Fluorouracil—urinary bladder cancer	0.000356	0.00347	CcSEcCtD
Repaglinide—Back pain—Gemcitabine—urinary bladder cancer	0.00035	0.00341	CcSEcCtD
Repaglinide—Immune system disorder—Cisplatin—urinary bladder cancer	0.00035	0.00341	CcSEcCtD
Repaglinide—Arrhythmia—Cisplatin—urinary bladder cancer	0.000346	0.00337	CcSEcCtD
Repaglinide—Thrombocytopenia—Thiotepa—urinary bladder cancer	0.000343	0.00335	CcSEcCtD
Repaglinide—Alopecia—Cisplatin—urinary bladder cancer	0.000342	0.00334	CcSEcCtD
Repaglinide—Skin disorder—Thiotepa—urinary bladder cancer	0.000341	0.00332	CcSEcCtD
Repaglinide—Malnutrition—Cisplatin—urinary bladder cancer	0.000337	0.00329	CcSEcCtD
Repaglinide—Erythema—Cisplatin—urinary bladder cancer	0.000337	0.00329	CcSEcCtD
Repaglinide—Erythema multiforme—Etoposide—urinary bladder cancer	0.000335	0.00327	CcSEcCtD
Repaglinide—Eye disorder—Etoposide—urinary bladder cancer	0.000331	0.00323	CcSEcCtD
Repaglinide—Cardiac disorder—Etoposide—urinary bladder cancer	0.000329	0.00321	CcSEcCtD
Repaglinide—Hepatic function abnormal—Epirubicin—urinary bladder cancer	0.000329	0.00321	CcSEcCtD
Repaglinide—Visual disturbance—Methotrexate—urinary bladder cancer	0.000324	0.00316	CcSEcCtD
Repaglinide—Leukopenia—Gemcitabine—urinary bladder cancer	0.000324	0.00316	CcSEcCtD
Repaglinide—Immune system disorder—Etoposide—urinary bladder cancer	0.00032	0.00312	CcSEcCtD
Repaglinide—Musculoskeletal discomfort—Thiotepa—urinary bladder cancer	0.00032	0.00312	CcSEcCtD
Repaglinide—Leukopenia—Fluorouracil—urinary bladder cancer	0.000318	0.0031	CcSEcCtD
Repaglinide—Anaphylactoid reaction—Methotrexate—urinary bladder cancer	0.000317	0.0031	CcSEcCtD
Repaglinide—Cardiac failure congestive—Epirubicin—urinary bladder cancer	0.000317	0.00309	CcSEcCtD
Repaglinide—Paraesthesia—Thiotepa—urinary bladder cancer	0.000315	0.00307	CcSEcCtD
Repaglinide—Alopecia—Etoposide—urinary bladder cancer	0.000313	0.00306	CcSEcCtD
Repaglinide—Hypertension—Gemcitabine—urinary bladder cancer	0.000312	0.00305	CcSEcCtD
Repaglinide—Dyspepsia—Thiotepa—urinary bladder cancer	0.000309	0.00301	CcSEcCtD
Repaglinide—Chest pain—Gemcitabine—urinary bladder cancer	0.000308	0.003	CcSEcCtD
Repaglinide—Arthralgia—Gemcitabine—urinary bladder cancer	0.000308	0.003	CcSEcCtD
Repaglinide—Unspecified disorder of skin and subcutaneous tissue—Gemcitabine—urinary bladder cancer	0.000306	0.00298	CcSEcCtD
Repaglinide—Hepatic function abnormal—Doxorubicin—urinary bladder cancer	0.000304	0.00297	CcSEcCtD
Repaglinide—Gastrointestinal disorder—Thiotepa—urinary bladder cancer	0.000303	0.00295	CcSEcCtD
Repaglinide—Chest pain—Fluorouracil—urinary bladder cancer	0.000303	0.00295	CcSEcCtD
Repaglinide—Leukopenia—Cisplatin—urinary bladder cancer	0.000302	0.00294	CcSEcCtD
Repaglinide—Constipation—Thiotepa—urinary bladder cancer	0.0003	0.00293	CcSEcCtD
Repaglinide—Back pain—Etoposide—urinary bladder cancer	0.000299	0.00291	CcSEcCtD
Repaglinide—Anaphylactoid reaction—Epirubicin—urinary bladder cancer	0.000297	0.0029	CcSEcCtD
Repaglinide—Oedema—Gemcitabine—urinary bladder cancer	0.000295	0.00288	CcSEcCtD
Repaglinide—Anaphylactic shock—Gemcitabine—urinary bladder cancer	0.000295	0.00288	CcSEcCtD
Repaglinide—Hypoglycaemia—Epirubicin—urinary bladder cancer	0.000294	0.00287	CcSEcCtD
Repaglinide—Cardiac failure congestive—Doxorubicin—urinary bladder cancer	0.000293	0.00286	CcSEcCtD
Repaglinide—Oedema—Fluorouracil—urinary bladder cancer	0.00029	0.00283	CcSEcCtD
Repaglinide—Anaphylactic shock—Fluorouracil—urinary bladder cancer	0.00029	0.00283	CcSEcCtD
Repaglinide—Thrombocytopenia—Gemcitabine—urinary bladder cancer	0.000289	0.00282	CcSEcCtD
Repaglinide—Gastrointestinal pain—Thiotepa—urinary bladder cancer	0.000287	0.0028	CcSEcCtD
Repaglinide—Skin disorder—Gemcitabine—urinary bladder cancer	0.000287	0.0028	CcSEcCtD
Repaglinide—Unspecified disorder of skin and subcutaneous tissue—Cisplatin—urinary bladder cancer	0.000285	0.00278	CcSEcCtD
Repaglinide—Thrombocytopenia—Fluorouracil—urinary bladder cancer	0.000284	0.00277	CcSEcCtD
Repaglinide—Urticaria—Thiotepa—urinary bladder cancer	0.000279	0.00272	CcSEcCtD
Repaglinide—Abdominal pain—Thiotepa—urinary bladder cancer	0.000277	0.00271	CcSEcCtD
Repaglinide—Leukopenia—Etoposide—urinary bladder cancer	0.000276	0.0027	CcSEcCtD
Repaglinide—Anaphylactic shock—Cisplatin—urinary bladder cancer	0.000275	0.00268	CcSEcCtD
Repaglinide—Oedema—Cisplatin—urinary bladder cancer	0.000275	0.00268	CcSEcCtD
Repaglinide—Anaphylactoid reaction—Doxorubicin—urinary bladder cancer	0.000275	0.00268	CcSEcCtD
Repaglinide—Hypoglycaemia—Doxorubicin—urinary bladder cancer	0.000272	0.00266	CcSEcCtD
Repaglinide—Thrombocytopenia—Cisplatin—urinary bladder cancer	0.000269	0.00263	CcSEcCtD
Repaglinide—Musculoskeletal discomfort—Gemcitabine—urinary bladder cancer	0.000269	0.00262	CcSEcCtD
Repaglinide—Skin disorder—Cisplatin—urinary bladder cancer	0.000267	0.00261	CcSEcCtD
Repaglinide—Hypertension—Etoposide—urinary bladder cancer	0.000267	0.0026	CcSEcCtD
Repaglinide—Paraesthesia—Gemcitabine—urinary bladder cancer	0.000265	0.00258	CcSEcCtD
Repaglinide—Musculoskeletal discomfort—Fluorouracil—urinary bladder cancer	0.000264	0.00258	CcSEcCtD
Repaglinide—Chest pain—Etoposide—urinary bladder cancer	0.000263	0.00256	CcSEcCtD
Repaglinide—Unspecified disorder of skin and subcutaneous tissue—Etoposide—urinary bladder cancer	0.000261	0.00255	CcSEcCtD
Repaglinide—Paraesthesia—Fluorouracil—urinary bladder cancer	0.000261	0.00254	CcSEcCtD
Repaglinide—Pancreatitis—Methotrexate—urinary bladder cancer	0.00026	0.00254	CcSEcCtD
Repaglinide—Hypersensitivity—Thiotepa—urinary bladder cancer	0.000258	0.00252	CcSEcCtD
Repaglinide—Dyspepsia—Fluorouracil—urinary bladder cancer	0.000255	0.00249	CcSEcCtD
Repaglinide—Gastrointestinal disorder—Gemcitabine—urinary bladder cancer	0.000255	0.00249	CcSEcCtD
Repaglinide—Constipation—Gemcitabine—urinary bladder cancer	0.000252	0.00246	CcSEcCtD
Repaglinide—Anaphylactic shock—Etoposide—urinary bladder cancer	0.000252	0.00246	CcSEcCtD
Repaglinide—Musculoskeletal discomfort—Cisplatin—urinary bladder cancer	0.000251	0.00244	CcSEcCtD
Repaglinide—Gastrointestinal disorder—Fluorouracil—urinary bladder cancer	0.000251	0.00244	CcSEcCtD
Repaglinide—Pruritus—Thiotepa—urinary bladder cancer	0.000248	0.00242	CcSEcCtD
Repaglinide—Paraesthesia—Cisplatin—urinary bladder cancer	0.000247	0.00241	CcSEcCtD
Repaglinide—Thrombocytopenia—Etoposide—urinary bladder cancer	0.000247	0.00241	CcSEcCtD
Repaglinide—Skin disorder—Etoposide—urinary bladder cancer	0.000245	0.00239	CcSEcCtD
Repaglinide—Pancreatitis—Epirubicin—urinary bladder cancer	0.000244	0.00238	CcSEcCtD
Repaglinide—Angina pectoris—Epirubicin—urinary bladder cancer	0.000242	0.00236	CcSEcCtD
Repaglinide—Diarrhoea—Thiotepa—urinary bladder cancer	0.00024	0.00234	CcSEcCtD
Repaglinide—Bronchitis—Epirubicin—urinary bladder cancer	0.000239	0.00233	CcSEcCtD
Repaglinide—Gastrointestinal disorder—Cisplatin—urinary bladder cancer	0.000237	0.00232	CcSEcCtD
Repaglinide—Stevens-Johnson syndrome—Methotrexate—urinary bladder cancer	0.000235	0.00229	CcSEcCtD
Repaglinide—Urticaria—Fluorouracil—urinary bladder cancer	0.000231	0.00225	CcSEcCtD
Repaglinide—Paraesthesia—Etoposide—urinary bladder cancer	0.000226	0.00221	CcSEcCtD
Repaglinide—Pancreatitis—Doxorubicin—urinary bladder cancer	0.000225	0.0022	CcSEcCtD
Repaglinide—Hyperglycaemia—Epirubicin—urinary bladder cancer	0.000224	0.00219	CcSEcCtD
Repaglinide—Angina pectoris—Doxorubicin—urinary bladder cancer	0.000224	0.00218	CcSEcCtD
Repaglinide—Hepatobiliary disease—Methotrexate—urinary bladder cancer	0.000224	0.00218	CcSEcCtD
Repaglinide—Vomiting—Thiotepa—urinary bladder cancer	0.000223	0.00218	CcSEcCtD
Repaglinide—Rash—Thiotepa—urinary bladder cancer	0.000221	0.00216	CcSEcCtD
Repaglinide—Bronchitis—Doxorubicin—urinary bladder cancer	0.000221	0.00216	CcSEcCtD
Repaglinide—Dermatitis—Thiotepa—urinary bladder cancer	0.000221	0.00216	CcSEcCtD
Repaglinide—Headache—Thiotepa—urinary bladder cancer	0.00022	0.00214	CcSEcCtD
Repaglinide—Stevens-Johnson syndrome—Epirubicin—urinary bladder cancer	0.00022	0.00214	CcSEcCtD
Repaglinide—Gastrointestinal disorder—Etoposide—urinary bladder cancer	0.000218	0.00212	CcSEcCtD
Repaglinide—Jaundice—Epirubicin—urinary bladder cancer	0.000216	0.00211	CcSEcCtD
Repaglinide—Constipation—Etoposide—urinary bladder cancer	0.000215	0.0021	CcSEcCtD
Repaglinide—Urinary tract infection—Epirubicin—urinary bladder cancer	0.000215	0.0021	CcSEcCtD
Repaglinide—Hypersensitivity—Fluorouracil—urinary bladder cancer	0.000214	0.00209	CcSEcCtD
Repaglinide—Hepatitis—Methotrexate—urinary bladder cancer	0.000212	0.00207	CcSEcCtD
Repaglinide—Hepatobiliary disease—Epirubicin—urinary bladder cancer	0.000209	0.00204	CcSEcCtD
Repaglinide—Pruritus—Gemcitabine—urinary bladder cancer	0.000209	0.00204	CcSEcCtD
Repaglinide—Nausea—Thiotepa—urinary bladder cancer	0.000208	0.00203	CcSEcCtD
Repaglinide—Sinusitis—Epirubicin—urinary bladder cancer	0.000208	0.00203	CcSEcCtD
Repaglinide—Hyperglycaemia—Doxorubicin—urinary bladder cancer	0.000207	0.00202	CcSEcCtD
Repaglinide—Gastrointestinal pain—Etoposide—urinary bladder cancer	0.000206	0.00201	CcSEcCtD
Repaglinide—Pruritus—Fluorouracil—urinary bladder cancer	0.000205	0.002	CcSEcCtD
Repaglinide—Visual impairment—Methotrexate—urinary bladder cancer	0.000205	0.002	CcSEcCtD
Repaglinide—Stevens-Johnson syndrome—Doxorubicin—urinary bladder cancer	0.000203	0.00198	CcSEcCtD
Repaglinide—Hypersensitivity—Cisplatin—urinary bladder cancer	0.000203	0.00198	CcSEcCtD
Repaglinide—Diarrhoea—Gemcitabine—urinary bladder cancer	0.000202	0.00197	CcSEcCtD
Repaglinide—Erythema multiforme—Methotrexate—urinary bladder cancer	0.000201	0.00196	CcSEcCtD
Repaglinide—Urticaria—Etoposide—urinary bladder cancer	0.0002	0.00195	CcSEcCtD
Repaglinide—Jaundice—Doxorubicin—urinary bladder cancer	0.0002	0.00195	CcSEcCtD
Repaglinide—Rhinitis—Epirubicin—urinary bladder cancer	0.000199	0.00194	CcSEcCtD
Repaglinide—Abdominal pain—Etoposide—urinary bladder cancer	0.000199	0.00194	CcSEcCtD
Repaglinide—Urinary tract infection—Doxorubicin—urinary bladder cancer	0.000199	0.00194	CcSEcCtD
Repaglinide—Hepatitis—Epirubicin—urinary bladder cancer	0.000199	0.00194	CcSEcCtD
Repaglinide—Eye disorder—Methotrexate—urinary bladder cancer	0.000199	0.00194	CcSEcCtD
Repaglinide—Diarrhoea—Fluorouracil—urinary bladder cancer	0.000199	0.00194	CcSEcCtD
Repaglinide—Cardiac disorder—Methotrexate—urinary bladder cancer	0.000197	0.00192	CcSEcCtD
Repaglinide—Oedema peripheral—Epirubicin—urinary bladder cancer	0.000196	0.00191	CcSEcCtD
Repaglinide—Hepatobiliary disease—Doxorubicin—urinary bladder cancer	0.000194	0.00189	CcSEcCtD
Repaglinide—Sinusitis—Doxorubicin—urinary bladder cancer	0.000192	0.00188	CcSEcCtD
Repaglinide—Immune system disorder—Methotrexate—urinary bladder cancer	0.000192	0.00187	CcSEcCtD
Repaglinide—Visual impairment—Epirubicin—urinary bladder cancer	0.000192	0.00187	CcSEcCtD
Repaglinide—Diarrhoea—Cisplatin—urinary bladder cancer	0.000188	0.00184	CcSEcCtD
Repaglinide—Erythema multiforme—Epirubicin—urinary bladder cancer	0.000188	0.00183	CcSEcCtD
Repaglinide—Alopecia—Methotrexate—urinary bladder cancer	0.000188	0.00183	CcSEcCtD
Repaglinide—Vomiting—Gemcitabine—urinary bladder cancer	0.000188	0.00183	CcSEcCtD
Repaglinide—Rash—Gemcitabine—urinary bladder cancer	0.000186	0.00181	CcSEcCtD
Repaglinide—Dermatitis—Gemcitabine—urinary bladder cancer	0.000186	0.00181	CcSEcCtD
Repaglinide—Eye disorder—Epirubicin—urinary bladder cancer	0.000186	0.00181	CcSEcCtD
Repaglinide—Hypersensitivity—Etoposide—urinary bladder cancer	0.000186	0.00181	CcSEcCtD
Repaglinide—Malnutrition—Methotrexate—urinary bladder cancer	0.000185	0.0018	CcSEcCtD
Repaglinide—Erythema—Methotrexate—urinary bladder cancer	0.000185	0.0018	CcSEcCtD
Repaglinide—Headache—Gemcitabine—urinary bladder cancer	0.000185	0.0018	CcSEcCtD
Repaglinide—Cardiac disorder—Epirubicin—urinary bladder cancer	0.000185	0.0018	CcSEcCtD
Repaglinide—Vomiting—Fluorouracil—urinary bladder cancer	0.000184	0.0018	CcSEcCtD
Repaglinide—Rhinitis—Doxorubicin—urinary bladder cancer	0.000184	0.0018	CcSEcCtD
Repaglinide—Hepatitis—Doxorubicin—urinary bladder cancer	0.000184	0.00179	CcSEcCtD
Repaglinide—Rash—Fluorouracil—urinary bladder cancer	0.000183	0.00178	CcSEcCtD
Repaglinide—Dermatitis—Fluorouracil—urinary bladder cancer	0.000183	0.00178	CcSEcCtD
Repaglinide—Headache—Fluorouracil—urinary bladder cancer	0.000182	0.00177	CcSEcCtD
Repaglinide—Oedema peripheral—Doxorubicin—urinary bladder cancer	0.000181	0.00177	CcSEcCtD
Repaglinide—Immune system disorder—Epirubicin—urinary bladder cancer	0.00018	0.00175	CcSEcCtD
Repaglinide—Back pain—Methotrexate—urinary bladder cancer	0.000179	0.00174	CcSEcCtD
Repaglinide—Pruritus—Etoposide—urinary bladder cancer	0.000178	0.00174	CcSEcCtD
Repaglinide—Arrhythmia—Epirubicin—urinary bladder cancer	0.000178	0.00173	CcSEcCtD
Repaglinide—Visual impairment—Doxorubicin—urinary bladder cancer	0.000177	0.00173	CcSEcCtD
Repaglinide—Alopecia—Epirubicin—urinary bladder cancer	0.000176	0.00171	CcSEcCtD
Repaglinide—Nausea—Gemcitabine—urinary bladder cancer	0.000175	0.00171	CcSEcCtD
Repaglinide—Vomiting—Cisplatin—urinary bladder cancer	0.000175	0.00171	CcSEcCtD
Repaglinide—Erythema multiforme—Doxorubicin—urinary bladder cancer	0.000174	0.0017	CcSEcCtD
Repaglinide—Rash—Cisplatin—urinary bladder cancer	0.000173	0.00169	CcSEcCtD
Repaglinide—Dermatitis—Cisplatin—urinary bladder cancer	0.000173	0.00169	CcSEcCtD
Repaglinide—Malnutrition—Epirubicin—urinary bladder cancer	0.000173	0.00169	CcSEcCtD
Repaglinide—Erythema—Epirubicin—urinary bladder cancer	0.000173	0.00169	CcSEcCtD
Repaglinide—Diarrhoea—Etoposide—urinary bladder cancer	0.000172	0.00168	CcSEcCtD
Repaglinide—Nausea—Fluorouracil—urinary bladder cancer	0.000172	0.00168	CcSEcCtD
Repaglinide—Eye disorder—Doxorubicin—urinary bladder cancer	0.000172	0.00168	CcSEcCtD
Repaglinide—Cardiac disorder—Doxorubicin—urinary bladder cancer	0.000171	0.00167	CcSEcCtD
Repaglinide—Back pain—Epirubicin—urinary bladder cancer	0.000167	0.00163	CcSEcCtD
Repaglinide—Immune system disorder—Doxorubicin—urinary bladder cancer	0.000166	0.00162	CcSEcCtD
Repaglinide—Leukopenia—Methotrexate—urinary bladder cancer	0.000166	0.00161	CcSEcCtD
Repaglinide—Arrhythmia—Doxorubicin—urinary bladder cancer	0.000164	0.0016	CcSEcCtD
Repaglinide—Nausea—Cisplatin—urinary bladder cancer	0.000163	0.00159	CcSEcCtD
Repaglinide—Alopecia—Doxorubicin—urinary bladder cancer	0.000163	0.00159	CcSEcCtD
Repaglinide—Vomiting—Etoposide—urinary bladder cancer	0.00016	0.00156	CcSEcCtD
Repaglinide—Erythema—Doxorubicin—urinary bladder cancer	0.00016	0.00156	CcSEcCtD
Repaglinide—Malnutrition—Doxorubicin—urinary bladder cancer	0.00016	0.00156	CcSEcCtD
Repaglinide—Rash—Etoposide—urinary bladder cancer	0.000159	0.00155	CcSEcCtD
Repaglinide—Dermatitis—Etoposide—urinary bladder cancer	0.000159	0.00155	CcSEcCtD
Repaglinide—Headache—Etoposide—urinary bladder cancer	0.000158	0.00154	CcSEcCtD
Repaglinide—Arthralgia—Methotrexate—urinary bladder cancer	0.000157	0.00154	CcSEcCtD
Repaglinide—Chest pain—Methotrexate—urinary bladder cancer	0.000157	0.00154	CcSEcCtD
Repaglinide—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—urinary bladder cancer	0.000156	0.00153	CcSEcCtD
Repaglinide—Leukopenia—Epirubicin—urinary bladder cancer	0.000155	0.00151	CcSEcCtD
Repaglinide—Back pain—Doxorubicin—urinary bladder cancer	0.000155	0.00151	CcSEcCtD
Repaglinide—Palpitations—Epirubicin—urinary bladder cancer	0.000153	0.00149	CcSEcCtD
Repaglinide—Anaphylactic shock—Methotrexate—urinary bladder cancer	0.000151	0.00147	CcSEcCtD
Repaglinide—Nausea—Etoposide—urinary bladder cancer	0.00015	0.00146	CcSEcCtD
Repaglinide—Hypertension—Epirubicin—urinary bladder cancer	0.000149	0.00146	CcSEcCtD
Repaglinide—Thrombocytopenia—Methotrexate—urinary bladder cancer	0.000148	0.00144	CcSEcCtD
Repaglinide—Arthralgia—Epirubicin—urinary bladder cancer	0.000147	0.00144	CcSEcCtD
Repaglinide—Chest pain—Epirubicin—urinary bladder cancer	0.000147	0.00144	CcSEcCtD
Repaglinide—Skin disorder—Methotrexate—urinary bladder cancer	0.000147	0.00143	CcSEcCtD
Repaglinide—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—urinary bladder cancer	0.000146	0.00143	CcSEcCtD
Repaglinide—Leukopenia—Doxorubicin—urinary bladder cancer	0.000143	0.0014	CcSEcCtD
Repaglinide—Palpitations—Doxorubicin—urinary bladder cancer	0.000142	0.00138	CcSEcCtD
Repaglinide—Oedema—Epirubicin—urinary bladder cancer	0.000141	0.00138	CcSEcCtD
Repaglinide—Anaphylactic shock—Epirubicin—urinary bladder cancer	0.000141	0.00138	CcSEcCtD
Repaglinide—Thrombocytopenia—Epirubicin—urinary bladder cancer	0.000138	0.00135	CcSEcCtD
Repaglinide—Hypertension—Doxorubicin—urinary bladder cancer	0.000138	0.00135	CcSEcCtD
Repaglinide—Musculoskeletal discomfort—Methotrexate—urinary bladder cancer	0.000138	0.00134	CcSEcCtD
Repaglinide—Skin disorder—Epirubicin—urinary bladder cancer	0.000137	0.00134	CcSEcCtD
Repaglinide—Arthralgia—Doxorubicin—urinary bladder cancer	0.000136	0.00133	CcSEcCtD
Repaglinide—Chest pain—Doxorubicin—urinary bladder cancer	0.000136	0.00133	CcSEcCtD
Repaglinide—Paraesthesia—Methotrexate—urinary bladder cancer	0.000136	0.00132	CcSEcCtD
Repaglinide—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—urinary bladder cancer	0.000135	0.00132	CcSEcCtD
Repaglinide—Dyspepsia—Methotrexate—urinary bladder cancer	0.000133	0.0013	CcSEcCtD
Repaglinide—Anaphylactic shock—Doxorubicin—urinary bladder cancer	0.000131	0.00127	CcSEcCtD
Repaglinide—Oedema—Doxorubicin—urinary bladder cancer	0.000131	0.00127	CcSEcCtD
Repaglinide—Gastrointestinal disorder—Methotrexate—urinary bladder cancer	0.00013	0.00127	CcSEcCtD
Repaglinide—Musculoskeletal discomfort—Epirubicin—urinary bladder cancer	0.000129	0.00126	CcSEcCtD
Repaglinide—Thrombocytopenia—Doxorubicin—urinary bladder cancer	0.000128	0.00125	CcSEcCtD
Repaglinide—Skin disorder—Doxorubicin—urinary bladder cancer	0.000127	0.00124	CcSEcCtD
Repaglinide—Paraesthesia—Epirubicin—urinary bladder cancer	0.000127	0.00124	CcSEcCtD
Repaglinide—Dyspepsia—Epirubicin—urinary bladder cancer	0.000124	0.00121	CcSEcCtD
Repaglinide—Gastrointestinal pain—Methotrexate—urinary bladder cancer	0.000123	0.0012	CcSEcCtD
Repaglinide—Gastrointestinal disorder—Epirubicin—urinary bladder cancer	0.000122	0.00119	CcSEcCtD
Repaglinide—Constipation—Epirubicin—urinary bladder cancer	0.000121	0.00118	CcSEcCtD
Repaglinide—Urticaria—Methotrexate—urinary bladder cancer	0.00012	0.00117	CcSEcCtD
Repaglinide—Abdominal pain—Methotrexate—urinary bladder cancer	0.000119	0.00116	CcSEcCtD
Repaglinide—Musculoskeletal discomfort—Doxorubicin—urinary bladder cancer	0.000119	0.00116	CcSEcCtD
Repaglinide—Paraesthesia—Doxorubicin—urinary bladder cancer	0.000117	0.00114	CcSEcCtD
Repaglinide—Gastrointestinal pain—Epirubicin—urinary bladder cancer	0.000116	0.00113	CcSEcCtD
Repaglinide—Dyspepsia—Doxorubicin—urinary bladder cancer	0.000115	0.00112	CcSEcCtD
Repaglinide—Gastrointestinal disorder—Doxorubicin—urinary bladder cancer	0.000113	0.0011	CcSEcCtD
Repaglinide—Urticaria—Epirubicin—urinary bladder cancer	0.000112	0.00109	CcSEcCtD
Repaglinide—Constipation—Doxorubicin—urinary bladder cancer	0.000112	0.00109	CcSEcCtD
Repaglinide—Abdominal pain—Epirubicin—urinary bladder cancer	0.000112	0.00109	CcSEcCtD
Repaglinide—Hypersensitivity—Methotrexate—urinary bladder cancer	0.000111	0.00108	CcSEcCtD
Repaglinide—Gastrointestinal pain—Doxorubicin—urinary bladder cancer	0.000107	0.00104	CcSEcCtD
Repaglinide—Pruritus—Methotrexate—urinary bladder cancer	0.000107	0.00104	CcSEcCtD
Repaglinide—Hypersensitivity—Epirubicin—urinary bladder cancer	0.000104	0.00102	CcSEcCtD
Repaglinide—Urticaria—Doxorubicin—urinary bladder cancer	0.000104	0.00101	CcSEcCtD
Repaglinide—Abdominal pain—Doxorubicin—urinary bladder cancer	0.000103	0.00101	CcSEcCtD
Repaglinide—Diarrhoea—Methotrexate—urinary bladder cancer	0.000103	0.00101	CcSEcCtD
Repaglinide—Pruritus—Epirubicin—urinary bladder cancer	9.99e-05	0.000975	CcSEcCtD
Repaglinide—Diarrhoea—Epirubicin—urinary bladder cancer	9.66e-05	0.000943	CcSEcCtD
Repaglinide—Hypersensitivity—Doxorubicin—urinary bladder cancer	9.63e-05	0.000939	CcSEcCtD
Repaglinide—Vomiting—Methotrexate—urinary bladder cancer	9.6e-05	0.000936	CcSEcCtD
Repaglinide—Rash—Methotrexate—urinary bladder cancer	9.52e-05	0.000928	CcSEcCtD
Repaglinide—Dermatitis—Methotrexate—urinary bladder cancer	9.51e-05	0.000927	CcSEcCtD
Repaglinide—Headache—Methotrexate—urinary bladder cancer	9.46e-05	0.000922	CcSEcCtD
Repaglinide—Pruritus—Doxorubicin—urinary bladder cancer	9.25e-05	0.000902	CcSEcCtD
Repaglinide—Vomiting—Epirubicin—urinary bladder cancer	8.98e-05	0.000876	CcSEcCtD
Repaglinide—Nausea—Methotrexate—urinary bladder cancer	8.97e-05	0.000875	CcSEcCtD
Repaglinide—Diarrhoea—Doxorubicin—urinary bladder cancer	8.94e-05	0.000872	CcSEcCtD
Repaglinide—Rash—Epirubicin—urinary bladder cancer	8.91e-05	0.000869	CcSEcCtD
Repaglinide—Dermatitis—Epirubicin—urinary bladder cancer	8.9e-05	0.000868	CcSEcCtD
Repaglinide—Headache—Epirubicin—urinary bladder cancer	8.85e-05	0.000863	CcSEcCtD
Repaglinide—Nausea—Epirubicin—urinary bladder cancer	8.39e-05	0.000818	CcSEcCtD
Repaglinide—Vomiting—Doxorubicin—urinary bladder cancer	8.31e-05	0.000811	CcSEcCtD
Repaglinide—Rash—Doxorubicin—urinary bladder cancer	8.24e-05	0.000804	CcSEcCtD
Repaglinide—Dermatitis—Doxorubicin—urinary bladder cancer	8.23e-05	0.000803	CcSEcCtD
Repaglinide—Headache—Doxorubicin—urinary bladder cancer	8.19e-05	0.000799	CcSEcCtD
Repaglinide—Nausea—Doxorubicin—urinary bladder cancer	7.76e-05	0.000757	CcSEcCtD
Repaglinide—ABCC8—Metabolism—NAT2—urinary bladder cancer	6.2e-05	0.00136	CbGpPWpGaD
Repaglinide—PPARG—Metabolism—PRSS3—urinary bladder cancer	6.14e-05	0.00134	CbGpPWpGaD
Repaglinide—PPARG—Adipogenesis—TNF—urinary bladder cancer	6.11e-05	0.00134	CbGpPWpGaD
Repaglinide—KCNJ11—Metabolism—NAT2—urinary bladder cancer	6.01e-05	0.00132	CbGpPWpGaD
Repaglinide—PPARG—Generic Transcription Pathway—NCOR1—urinary bladder cancer	5.86e-05	0.00128	CbGpPWpGaD
Repaglinide—SLCO1B1—Metabolism—UGT2B7—urinary bladder cancer	5.84e-05	0.00128	CbGpPWpGaD
Repaglinide—ALB—Vitamin B12 Metabolism—TNF—urinary bladder cancer	5.81e-05	0.00127	CbGpPWpGaD
Repaglinide—CYP2C8—Biological oxidations—GSTM1—urinary bladder cancer	5.8e-05	0.00127	CbGpPWpGaD
Repaglinide—PPARG—Fatty acid, triacylglycerol, and ketone body metabolism—EP300—urinary bladder cancer	5.8e-05	0.00127	CbGpPWpGaD
Repaglinide—CYP2C8—Metapathway biotransformation—GSTM1—urinary bladder cancer	5.72e-05	0.00125	CbGpPWpGaD
Repaglinide—ALB—Transmembrane transport of small molecules—AQP3—urinary bladder cancer	5.63e-05	0.00123	CbGpPWpGaD
Repaglinide—PPARG—Circadian rythm related genes—PTEN—urinary bladder cancer	5.57e-05	0.00122	CbGpPWpGaD
Repaglinide—ALB—Selenium Micronutrient Network—PTGS2—urinary bladder cancer	5.56e-05	0.00122	CbGpPWpGaD
Repaglinide—PPARG—Developmental Biology—NCOR1—urinary bladder cancer	5.51e-05	0.00121	CbGpPWpGaD
Repaglinide—SLCO1B1—Transmembrane transport of small molecules—TFRC—urinary bladder cancer	5.42e-05	0.00119	CbGpPWpGaD
Repaglinide—ABCC8—Metabolism—RRM2—urinary bladder cancer	5.35e-05	0.00117	CbGpPWpGaD
Repaglinide—PPARG—Circadian rythm related genes—EP300—urinary bladder cancer	5.31e-05	0.00116	CbGpPWpGaD
Repaglinide—SLCO1B1—Metabolism—CYP4B1—urinary bladder cancer	5.26e-05	0.00115	CbGpPWpGaD
Repaglinide—KCNJ11—Metabolism—RRM2—urinary bladder cancer	5.19e-05	0.00114	CbGpPWpGaD
Repaglinide—CYP3A4—Biological oxidations—HPGDS—urinary bladder cancer	5.04e-05	0.0011	CbGpPWpGaD
Repaglinide—SLCO1B1—Metabolism—SLC19A1—urinary bladder cancer	4.96e-05	0.00109	CbGpPWpGaD
Repaglinide—ABCC8—Metabolism—ENO2—urinary bladder cancer	4.95e-05	0.00108	CbGpPWpGaD
Repaglinide—ABCC8—Metabolism—HPGDS—urinary bladder cancer	4.95e-05	0.00108	CbGpPWpGaD
Repaglinide—PPARG—Metabolism of lipids and lipoproteins—NCOR1—urinary bladder cancer	4.92e-05	0.00108	CbGpPWpGaD
Repaglinide—PPARG—Metabolism—TYMP—urinary bladder cancer	4.91e-05	0.00107	CbGpPWpGaD
Repaglinide—CYP3A4—Biological oxidations—GSTT1—urinary bladder cancer	4.89e-05	0.00107	CbGpPWpGaD
Repaglinide—SLCO1B1—Metabolism—PRSS3—urinary bladder cancer	4.84e-05	0.00106	CbGpPWpGaD
Repaglinide—ABCC8—Metabolism—GSTT1—urinary bladder cancer	4.8e-05	0.00105	CbGpPWpGaD
Repaglinide—KCNJ11—Metabolism—ENO2—urinary bladder cancer	4.8e-05	0.00105	CbGpPWpGaD
Repaglinide—KCNJ11—Metabolism—HPGDS—urinary bladder cancer	4.8e-05	0.00105	CbGpPWpGaD
Repaglinide—ALB—Folate Metabolism—TNF—urinary bladder cancer	4.73e-05	0.00103	CbGpPWpGaD
Repaglinide—PPARG—Metabolism of lipids and lipoproteins—GPX1—urinary bladder cancer	4.72e-05	0.00103	CbGpPWpGaD
Repaglinide—KCNJ11—Metabolism—GSTT1—urinary bladder cancer	4.66e-05	0.00102	CbGpPWpGaD
Repaglinide—PPARG—Generic Transcription Pathway—ESR1—urinary bladder cancer	4.6e-05	0.00101	CbGpPWpGaD
Repaglinide—ALB—Transmembrane transport of small molecules—TRPV1—urinary bladder cancer	4.59e-05	0.001	CbGpPWpGaD
Repaglinide—ABCC8—Transmembrane transport of small molecules—CREBBP—urinary bladder cancer	4.5e-05	0.000985	CbGpPWpGaD
Repaglinide—PPARG—Metabolism—NAT2—urinary bladder cancer	4.44e-05	0.000972	CbGpPWpGaD
Repaglinide—PPARG—Developmental Biology—CDK4—urinary bladder cancer	4.35e-05	0.000952	CbGpPWpGaD
Repaglinide—PPARG—Gene Expression—SMC1A—urinary bladder cancer	4.19e-05	0.000917	CbGpPWpGaD
Repaglinide—ALB—Folate Metabolism—TP53—urinary bladder cancer	4.17e-05	0.000912	CbGpPWpGaD
Repaglinide—PPARG—Generic Transcription Pathway—CREBBP—urinary bladder cancer	4.03e-05	0.000883	CbGpPWpGaD
Repaglinide—ABCC8—Metabolism—NQO1—urinary bladder cancer	3.99e-05	0.000874	CbGpPWpGaD
Repaglinide—ABCC8—Neuronal System—HRAS—urinary bladder cancer	3.9e-05	0.000854	CbGpPWpGaD
Repaglinide—SLCO1B1—Metabolism of lipids and lipoproteins—NCOR1—urinary bladder cancer	3.88e-05	0.000849	CbGpPWpGaD
Repaglinide—KCNJ11—Metabolism—NQO1—urinary bladder cancer	3.87e-05	0.000847	CbGpPWpGaD
Repaglinide—CYP2C8—Metabolism—GSTZ1—urinary bladder cancer	3.87e-05	0.000847	CbGpPWpGaD
Repaglinide—SLCO1B1—Metabolism—TYMP—urinary bladder cancer	3.87e-05	0.000846	CbGpPWpGaD
Repaglinide—ALB—Metabolism—GSTZ1—urinary bladder cancer	3.85e-05	0.000842	CbGpPWpGaD
Repaglinide—PPARG—Metabolism—RRM2—urinary bladder cancer	3.83e-05	0.000839	CbGpPWpGaD
Repaglinide—PPARG—Circadian rythm related genes—TP53—urinary bladder cancer	3.8e-05	0.000831	CbGpPWpGaD
Repaglinide—PPARG—Developmental Biology—CREBBP—urinary bladder cancer	3.8e-05	0.000831	CbGpPWpGaD
Repaglinide—KCNJ11—Neuronal System—HRAS—urinary bladder cancer	3.78e-05	0.000828	CbGpPWpGaD
Repaglinide—ALB—Selenium Micronutrient Network—TNF—urinary bladder cancer	3.75e-05	0.000822	CbGpPWpGaD
Repaglinide—SLCO1B1—Metabolism of lipids and lipoproteins—GPX1—urinary bladder cancer	3.71e-05	0.000813	CbGpPWpGaD
Repaglinide—CYP2C8—Metabolism—GSTO2—urinary bladder cancer	3.67e-05	0.000803	CbGpPWpGaD
Repaglinide—CYP2C8—Metabolism—NAT1—urinary bladder cancer	3.67e-05	0.000803	CbGpPWpGaD
Repaglinide—PPARG—Gene Expression—ESR2—urinary bladder cancer	3.65e-05	0.0008	CbGpPWpGaD
Repaglinide—ALB—Metabolism—NAT1—urinary bladder cancer	3.65e-05	0.000798	CbGpPWpGaD
Repaglinide—ALB—Metabolism—GSTO2—urinary bladder cancer	3.65e-05	0.000798	CbGpPWpGaD
Repaglinide—CYP2C8—Metabolism of lipids and lipoproteins—HPGDS—urinary bladder cancer	3.61e-05	0.000789	CbGpPWpGaD
Repaglinide—ALB—Metabolism of lipids and lipoproteins—HPGDS—urinary bladder cancer	3.59e-05	0.000785	CbGpPWpGaD
Repaglinide—PPARG—Metabolism—HPGDS—urinary bladder cancer	3.55e-05	0.000777	CbGpPWpGaD
Repaglinide—PPARG—Metabolism—ENO2—urinary bladder cancer	3.55e-05	0.000777	CbGpPWpGaD
Repaglinide—SLCO1B1—Metabolism—NAT2—urinary bladder cancer	3.5e-05	0.000765	CbGpPWpGaD
Repaglinide—PPARG—Metabolism—GSTT1—urinary bladder cancer	3.44e-05	0.000754	CbGpPWpGaD
Repaglinide—PPARG—Developmental Biology—RHOA—urinary bladder cancer	3.43e-05	0.000752	CbGpPWpGaD
Repaglinide—PPARG—Metabolism of lipids and lipoproteins—CREBBP—urinary bladder cancer	3.39e-05	0.000742	CbGpPWpGaD
Repaglinide—CYP3A4—Biological oxidations—GSTP1—urinary bladder cancer	3.39e-05	0.000742	CbGpPWpGaD
Repaglinide—CYP2C8—Metabolism—UGT2B7—urinary bladder cancer	3.35e-05	0.000734	CbGpPWpGaD
Repaglinide—CYP3A4—Metapathway biotransformation—GSTP1—urinary bladder cancer	3.34e-05	0.000732	CbGpPWpGaD
Repaglinide—ALB—Metabolism—UGT2B7—urinary bladder cancer	3.33e-05	0.00073	CbGpPWpGaD
Repaglinide—ABCC8—Metabolism—GSTP1—urinary bladder cancer	3.33e-05	0.000729	CbGpPWpGaD
Repaglinide—KCNJ11—Metabolism—GSTP1—urinary bladder cancer	3.23e-05	0.000707	CbGpPWpGaD
Repaglinide—ALB—Platelet activation, signaling and aggregation—IGF1—urinary bladder cancer	3.21e-05	0.000703	CbGpPWpGaD
Repaglinide—PPARG—Developmental Biology—ERBB2—urinary bladder cancer	3.18e-05	0.000696	CbGpPWpGaD
Repaglinide—CYP3A4—Biological oxidations—GSTM1—urinary bladder cancer	3.11e-05	0.000682	CbGpPWpGaD
Repaglinide—ALB—Transmembrane transport of small molecules—TFRC—urinary bladder cancer	3.1e-05	0.000678	CbGpPWpGaD
Repaglinide—ABCC8—Metabolism—TYMS—urinary bladder cancer	3.1e-05	0.000678	CbGpPWpGaD
Repaglinide—CYP3A4—Metapathway biotransformation—GSTM1—urinary bladder cancer	3.07e-05	0.000672	CbGpPWpGaD
Repaglinide—ABCC8—Metabolism—NCOR1—urinary bladder cancer	3.06e-05	0.00067	CbGpPWpGaD
Repaglinide—ABCC8—Metabolism—GSTM1—urinary bladder cancer	3.06e-05	0.00067	CbGpPWpGaD
Repaglinide—CYP2C8—Metabolism—CYP4B1—urinary bladder cancer	3.02e-05	0.000661	CbGpPWpGaD
Repaglinide—SLCO1B1—Metabolism—RRM2—urinary bladder cancer	3.02e-05	0.000661	CbGpPWpGaD
Repaglinide—ALB—Metabolism—CYP4B1—urinary bladder cancer	3e-05	0.000657	CbGpPWpGaD
Repaglinide—KCNJ11—Metabolism—TYMS—urinary bladder cancer	3e-05	0.000657	CbGpPWpGaD
Repaglinide—KCNJ11—Metabolism—GSTM1—urinary bladder cancer	2.97e-05	0.00065	CbGpPWpGaD
Repaglinide—KCNJ11—Metabolism—NCOR1—urinary bladder cancer	2.97e-05	0.00065	CbGpPWpGaD
Repaglinide—ALB—Platelet activation, signaling and aggregation—RHOA—urinary bladder cancer	2.94e-05	0.000644	CbGpPWpGaD
Repaglinide—ABCC8—Metabolism—GPX1—urinary bladder cancer	2.93e-05	0.000641	CbGpPWpGaD
Repaglinide—ABCC8—Metabolism—ERCC2—urinary bladder cancer	2.88e-05	0.00063	CbGpPWpGaD
Repaglinide—ALB—Hemostasis—IFNA2—urinary bladder cancer	2.86e-05	0.000626	CbGpPWpGaD
Repaglinide—PPARG—Metabolism—NQO1—urinary bladder cancer	2.86e-05	0.000626	CbGpPWpGaD
Repaglinide—CYP2C8—Metabolism—SLC19A1—urinary bladder cancer	2.85e-05	0.000624	CbGpPWpGaD
Repaglinide—KCNJ11—Metabolism—GPX1—urinary bladder cancer	2.84e-05	0.000622	CbGpPWpGaD
Repaglinide—ALB—Metabolism—SLC19A1—urinary bladder cancer	2.84e-05	0.000621	CbGpPWpGaD
Repaglinide—PPARG—Gene Expression—NCOR1—urinary bladder cancer	2.82e-05	0.000617	CbGpPWpGaD
Repaglinide—SLCO1B1—Metabolism—HPGDS—urinary bladder cancer	2.8e-05	0.000612	CbGpPWpGaD
Repaglinide—SLCO1B1—Metabolism—ENO2—urinary bladder cancer	2.8e-05	0.000612	CbGpPWpGaD
Repaglinide—KCNJ11—Metabolism—ERCC2—urinary bladder cancer	2.79e-05	0.000611	CbGpPWpGaD
Repaglinide—CYP2C8—Metabolism—PRSS3—urinary bladder cancer	2.78e-05	0.000608	CbGpPWpGaD
Repaglinide—SLCO1B1—Metabolism of lipids and lipoproteins—PPARG—urinary bladder cancer	2.78e-05	0.000608	CbGpPWpGaD
Repaglinide—PPARG—Metabolism of lipids and lipoproteins—PTGS2—urinary bladder cancer	2.78e-05	0.000608	CbGpPWpGaD
Repaglinide—ALB—Metabolism—PRSS3—urinary bladder cancer	2.76e-05	0.000605	CbGpPWpGaD
Repaglinide—PPARG—Developmental Biology—MMP9—urinary bladder cancer	2.73e-05	0.000597	CbGpPWpGaD
Repaglinide—SLCO1B1—Metabolism—GSTT1—urinary bladder cancer	2.71e-05	0.000593	CbGpPWpGaD
Repaglinide—ABCC8—Metabolism—MTHFR—urinary bladder cancer	2.7e-05	0.000592	CbGpPWpGaD
Repaglinide—SLCO1B1—Metabolism of lipids and lipoproteins—CREBBP—urinary bladder cancer	2.67e-05	0.000584	CbGpPWpGaD
Repaglinide—PPARG—Gene Expression—ERCC2—urinary bladder cancer	2.65e-05	0.00058	CbGpPWpGaD
Repaglinide—KCNJ11—Metabolism—MTHFR—urinary bladder cancer	2.62e-05	0.000574	CbGpPWpGaD
Repaglinide—PPARG—Developmental Biology—EP300—urinary bladder cancer	2.59e-05	0.000566	CbGpPWpGaD
Repaglinide—SLCO1B1—Transmembrane transport of small molecules—CREBBP—urinary bladder cancer	2.54e-05	0.000556	CbGpPWpGaD
Repaglinide—PPARG—Developmental Biology—SRC—urinary bladder cancer	2.51e-05	0.00055	CbGpPWpGaD
Repaglinide—ALB—Platelet activation, signaling and aggregation—IL2—urinary bladder cancer	2.47e-05	0.00054	CbGpPWpGaD
Repaglinide—PPARG—Metabolism of lipids and lipoproteins—PTEN—urinary bladder cancer	2.42e-05	0.00053	CbGpPWpGaD
Repaglinide—PPARG—Generic Transcription Pathway—MYC—urinary bladder cancer	2.39e-05	0.000524	CbGpPWpGaD
Repaglinide—PPARG—Metabolism—GSTP1—urinary bladder cancer	2.39e-05	0.000522	CbGpPWpGaD
Repaglinide—PPARG—Metabolism of lipids and lipoproteins—EP300—urinary bladder cancer	2.31e-05	0.000505	CbGpPWpGaD
Repaglinide—SLCO1B1—Metabolism—NQO1—urinary bladder cancer	2.25e-05	0.000493	CbGpPWpGaD
Repaglinide—CYP2C8—Metabolism of lipids and lipoproteins—NCOR1—urinary bladder cancer	2.23e-05	0.000488	CbGpPWpGaD
Repaglinide—CYP2C8—Metabolism—TYMP—urinary bladder cancer	2.22e-05	0.000486	CbGpPWpGaD
Repaglinide—PPARG—Metabolism—TYMS—urinary bladder cancer	2.22e-05	0.000486	CbGpPWpGaD
Repaglinide—ALB—Metabolism of lipids and lipoproteins—NCOR1—urinary bladder cancer	2.22e-05	0.000485	CbGpPWpGaD
Repaglinide—PPARG—Gene Expression—ESR1—urinary bladder cancer	2.22e-05	0.000485	CbGpPWpGaD
Repaglinide—ALB—Metabolism—TYMP—urinary bladder cancer	2.21e-05	0.000484	CbGpPWpGaD
Repaglinide—PPARG—Developmental Biology—EGFR—urinary bladder cancer	2.2e-05	0.000482	CbGpPWpGaD
Repaglinide—PPARG—Metabolism—NCOR1—urinary bladder cancer	2.19e-05	0.00048	CbGpPWpGaD
Repaglinide—ABCC8—Metabolism—PPARG—urinary bladder cancer	2.19e-05	0.00048	CbGpPWpGaD
Repaglinide—PPARG—Metabolism—GSTM1—urinary bladder cancer	2.19e-05	0.00048	CbGpPWpGaD
Repaglinide—SLCO1B1—Metabolism of lipids and lipoproteins—PTGS2—urinary bladder cancer	2.19e-05	0.000479	CbGpPWpGaD
Repaglinide—ALB—Platelet activation, signaling and aggregation—SRC—urinary bladder cancer	2.15e-05	0.000471	CbGpPWpGaD
Repaglinide—CYP2C8—Metabolism of lipids and lipoproteins—GPX1—urinary bladder cancer	2.13e-05	0.000467	CbGpPWpGaD
Repaglinide—KCNJ11—Metabolism—PPARG—urinary bladder cancer	2.13e-05	0.000465	CbGpPWpGaD
Repaglinide—ALB—Metabolism of lipids and lipoproteins—GPX1—urinary bladder cancer	2.12e-05	0.000464	CbGpPWpGaD
Repaglinide—ABCC8—Metabolism—CREBBP—urinary bladder cancer	2.11e-05	0.000461	CbGpPWpGaD
Repaglinide—PPARG—Metabolism—GPX1—urinary bladder cancer	2.1e-05	0.00046	CbGpPWpGaD
Repaglinide—PPARG—Developmental Biology—TNF—urinary bladder cancer	2.1e-05	0.000459	CbGpPWpGaD
Repaglinide—PPARG—Developmental Biology—KRAS—urinary bladder cancer	2.08e-05	0.000456	CbGpPWpGaD
Repaglinide—CYP3A4—Metabolism—GSTZ1—urinary bladder cancer	2.08e-05	0.000454	CbGpPWpGaD
Repaglinide—PPARG—Metabolism—ERCC2—urinary bladder cancer	2.06e-05	0.000451	CbGpPWpGaD
Repaglinide—KCNJ11—Metabolism—CREBBP—urinary bladder cancer	2.04e-05	0.000447	CbGpPWpGaD
Repaglinide—ALB—Hemostasis—PLAU—urinary bladder cancer	2.03e-05	0.000445	CbGpPWpGaD
Repaglinide—CYP2C8—Metabolism—NAT2—urinary bladder cancer	2.01e-05	0.00044	CbGpPWpGaD
Repaglinide—ALB—Metabolism—NAT2—urinary bladder cancer	2e-05	0.000437	CbGpPWpGaD
Repaglinide—CYP3A4—Metabolism—NAT1—urinary bladder cancer	1.97e-05	0.000431	CbGpPWpGaD
Repaglinide—CYP3A4—Metabolism—GSTO2—urinary bladder cancer	1.97e-05	0.000431	CbGpPWpGaD
Repaglinide—PPARG—Gene Expression—CREBBP—urinary bladder cancer	1.94e-05	0.000425	CbGpPWpGaD
Repaglinide—PPARG—Metabolism—MTHFR—urinary bladder cancer	1.94e-05	0.000424	CbGpPWpGaD
Repaglinide—SLCO1B1—Metabolism of lipids and lipoproteins—PTEN—urinary bladder cancer	1.91e-05	0.000417	CbGpPWpGaD
Repaglinide—SLCO1B1—Metabolism—GSTP1—urinary bladder cancer	1.88e-05	0.000411	CbGpPWpGaD
Repaglinide—SLCO1B1—Metabolism of lipids and lipoproteins—EP300—urinary bladder cancer	1.82e-05	0.000398	CbGpPWpGaD
Repaglinide—CYP3A4—Metabolism—UGT2B7—urinary bladder cancer	1.8e-05	0.000394	CbGpPWpGaD
Repaglinide—PPARG—Developmental Biology—HRAS—urinary bladder cancer	1.77e-05	0.000387	CbGpPWpGaD
Repaglinide—SLCO1B1—Metabolism—TYMS—urinary bladder cancer	1.75e-05	0.000382	CbGpPWpGaD
Repaglinide—CYP2C8—Metabolism—RRM2—urinary bladder cancer	1.73e-05	0.00038	CbGpPWpGaD
Repaglinide—SLCO1B1—Metabolism—NCOR1—urinary bladder cancer	1.73e-05	0.000378	CbGpPWpGaD
Repaglinide—SLCO1B1—Metabolism—GSTM1—urinary bladder cancer	1.73e-05	0.000378	CbGpPWpGaD
Repaglinide—ABCC8—Metabolism—PTGS2—urinary bladder cancer	1.73e-05	0.000378	CbGpPWpGaD
Repaglinide—ALB—Metabolism—RRM2—urinary bladder cancer	1.72e-05	0.000377	CbGpPWpGaD
Repaglinide—ALB—Hemostasis—CREBBP—urinary bladder cancer	1.68e-05	0.000367	CbGpPWpGaD
Repaglinide—KCNJ11—Metabolism—PTGS2—urinary bladder cancer	1.67e-05	0.000366	CbGpPWpGaD
Repaglinide—ALB—Hemostasis—IGF1—urinary bladder cancer	1.65e-05	0.000362	CbGpPWpGaD
Repaglinide—SLCO1B1—Metabolism—GPX1—urinary bladder cancer	1.65e-05	0.000362	CbGpPWpGaD
Repaglinide—SLCO1B1—Metabolism—ERCC2—urinary bladder cancer	1.62e-05	0.000355	CbGpPWpGaD
Repaglinide—CYP3A4—Metabolism—CYP4B1—urinary bladder cancer	1.62e-05	0.000355	CbGpPWpGaD
Repaglinide—CYP2C8—Metabolism—HPGDS—urinary bladder cancer	1.61e-05	0.000352	CbGpPWpGaD
Repaglinide—CYP2C8—Metabolism—ENO2—urinary bladder cancer	1.61e-05	0.000352	CbGpPWpGaD
Repaglinide—ALB—Metabolism—ENO2—urinary bladder cancer	1.6e-05	0.00035	CbGpPWpGaD
Repaglinide—ALB—Metabolism—HPGDS—urinary bladder cancer	1.6e-05	0.00035	CbGpPWpGaD
Repaglinide—CYP2C8—Metabolism of lipids and lipoproteins—PPARG—urinary bladder cancer	1.6e-05	0.00035	CbGpPWpGaD
Repaglinide—ALB—Metabolism of lipids and lipoproteins—PPARG—urinary bladder cancer	1.59e-05	0.000348	CbGpPWpGaD
Repaglinide—CYP2C8—Metabolism—GSTT1—urinary bladder cancer	1.56e-05	0.000341	CbGpPWpGaD
Repaglinide—ALB—Metabolism—GSTT1—urinary bladder cancer	1.55e-05	0.000339	CbGpPWpGaD
Repaglinide—CYP2C8—Metabolism of lipids and lipoproteins—CREBBP—urinary bladder cancer	1.53e-05	0.000336	CbGpPWpGaD
Repaglinide—CYP3A4—Metabolism—SLC19A1—urinary bladder cancer	1.53e-05	0.000335	CbGpPWpGaD
Repaglinide—SLCO1B1—Metabolism—MTHFR—urinary bladder cancer	1.53e-05	0.000334	CbGpPWpGaD
Repaglinide—ALB—Metabolism of lipids and lipoproteins—CREBBP—urinary bladder cancer	1.53e-05	0.000334	CbGpPWpGaD
Repaglinide—ALB—Hemostasis—RHOA—urinary bladder cancer	1.52e-05	0.000332	CbGpPWpGaD
Repaglinide—PPARG—Metabolism—CREBBP—urinary bladder cancer	1.51e-05	0.00033	CbGpPWpGaD
Repaglinide—ABCC8—Metabolism—PTEN—urinary bladder cancer	1.5e-05	0.000329	CbGpPWpGaD
Repaglinide—CYP3A4—Metabolism—PRSS3—urinary bladder cancer	1.49e-05	0.000327	CbGpPWpGaD
Repaglinide—KCNJ11—Metabolism—PTEN—urinary bladder cancer	1.46e-05	0.000319	CbGpPWpGaD
Repaglinide—ALB—Transmembrane transport of small molecules—CREBBP—urinary bladder cancer	1.45e-05	0.000317	CbGpPWpGaD
Repaglinide—ABCC8—Metabolism—EP300—urinary bladder cancer	1.43e-05	0.000314	CbGpPWpGaD
Repaglinide—KCNJ11—Metabolism—EP300—urinary bladder cancer	1.39e-05	0.000305	CbGpPWpGaD
Repaglinide—CYP2C8—Metabolism—NQO1—urinary bladder cancer	1.29e-05	0.000283	CbGpPWpGaD
Repaglinide—ALB—Metabolism—NQO1—urinary bladder cancer	1.29e-05	0.000282	CbGpPWpGaD
Repaglinide—ALB—Hemostasis—IL2—urinary bladder cancer	1.27e-05	0.000278	CbGpPWpGaD
Repaglinide—CYP2C8—Metabolism of lipids and lipoproteins—PTGS2—urinary bladder cancer	1.26e-05	0.000275	CbGpPWpGaD
Repaglinide—ALB—Metabolism of lipids and lipoproteins—PTGS2—urinary bladder cancer	1.25e-05	0.000273	CbGpPWpGaD
Repaglinide—SLCO1B1—Metabolism—PPARG—urinary bladder cancer	1.24e-05	0.000271	CbGpPWpGaD
Repaglinide—PPARG—Metabolism—PTGS2—urinary bladder cancer	1.24e-05	0.000271	CbGpPWpGaD
Repaglinide—CYP3A4—Metabolism—TYMP—urinary bladder cancer	1.19e-05	0.000261	CbGpPWpGaD
Repaglinide—SLCO1B1—Metabolism—CREBBP—urinary bladder cancer	1.19e-05	0.00026	CbGpPWpGaD
Repaglinide—PPARG—Gene Expression—MYC—urinary bladder cancer	1.15e-05	0.000252	CbGpPWpGaD
Repaglinide—ALB—Hemostasis—EP300—urinary bladder cancer	1.14e-05	0.00025	CbGpPWpGaD
Repaglinide—ALB—Hemostasis—SRC—urinary bladder cancer	1.11e-05	0.000243	CbGpPWpGaD
Repaglinide—CYP2C8—Metabolism of lipids and lipoproteins—PTEN—urinary bladder cancer	1.1e-05	0.00024	CbGpPWpGaD
Repaglinide—ALB—Metabolism of lipids and lipoproteins—PTEN—urinary bladder cancer	1.09e-05	0.000238	CbGpPWpGaD
Repaglinide—CYP2C8—Metabolism—GSTP1—urinary bladder cancer	1.08e-05	0.000236	CbGpPWpGaD
Repaglinide—CYP3A4—Metabolism—NAT2—urinary bladder cancer	1.08e-05	0.000236	CbGpPWpGaD
Repaglinide—PPARG—Metabolism—PTEN—urinary bladder cancer	1.08e-05	0.000236	CbGpPWpGaD
Repaglinide—ALB—Metabolism—GSTP1—urinary bladder cancer	1.07e-05	0.000235	CbGpPWpGaD
Repaglinide—CYP2C8—Metabolism of lipids and lipoproteins—EP300—urinary bladder cancer	1.04e-05	0.000229	CbGpPWpGaD
Repaglinide—ALB—Metabolism of lipids and lipoproteins—EP300—urinary bladder cancer	1.04e-05	0.000227	CbGpPWpGaD
Repaglinide—PPARG—Metabolism—EP300—urinary bladder cancer	1.03e-05	0.000225	CbGpPWpGaD
Repaglinide—CYP2C8—Metabolism—TYMS—urinary bladder cancer	1e-05	0.00022	CbGpPWpGaD
Repaglinide—ALB—Metabolism—TYMS—urinary bladder cancer	9.98e-06	0.000218	CbGpPWpGaD
Repaglinide—CYP2C8—Metabolism—NCOR1—urinary bladder cancer	9.92e-06	0.000217	CbGpPWpGaD
Repaglinide—CYP2C8—Metabolism—GSTM1—urinary bladder cancer	9.92e-06	0.000217	CbGpPWpGaD
Repaglinide—ALB—Metabolism—GSTM1—urinary bladder cancer	9.87e-06	0.000216	CbGpPWpGaD
Repaglinide—ALB—Metabolism—NCOR1—urinary bladder cancer	9.87e-06	0.000216	CbGpPWpGaD
Repaglinide—SLCO1B1—Metabolism—PTGS2—urinary bladder cancer	9.74e-06	0.000213	CbGpPWpGaD
Repaglinide—CYP2C8—Metabolism—GPX1—urinary bladder cancer	9.5e-06	0.000208	CbGpPWpGaD
Repaglinide—ALB—Metabolism—GPX1—urinary bladder cancer	9.45e-06	0.000207	CbGpPWpGaD
Repaglinide—CYP2C8—Metabolism—ERCC2—urinary bladder cancer	9.33e-06	0.000204	CbGpPWpGaD
Repaglinide—CYP3A4—Metabolism—RRM2—urinary bladder cancer	9.31e-06	0.000204	CbGpPWpGaD
Repaglinide—ALB—Metabolism—ERCC2—urinary bladder cancer	9.28e-06	0.000203	CbGpPWpGaD
Repaglinide—ALB—Hemostasis—KRAS—urinary bladder cancer	9.19e-06	0.000201	CbGpPWpGaD
Repaglinide—CYP2C8—Metabolism—MTHFR—urinary bladder cancer	8.77e-06	0.000192	CbGpPWpGaD
Repaglinide—ALB—Metabolism—MTHFR—urinary bladder cancer	8.72e-06	0.000191	CbGpPWpGaD
Repaglinide—CYP3A4—Metabolism—ENO2—urinary bladder cancer	8.62e-06	0.000189	CbGpPWpGaD
Repaglinide—CYP3A4—Metabolism—HPGDS—urinary bladder cancer	8.62e-06	0.000189	CbGpPWpGaD
Repaglinide—SLCO1B1—Metabolism—PTEN—urinary bladder cancer	8.49e-06	0.000186	CbGpPWpGaD
Repaglinide—CYP3A4—Metabolism—GSTT1—urinary bladder cancer	8.36e-06	0.000183	CbGpPWpGaD
Repaglinide—ALB—Hemostasis—TP53—urinary bladder cancer	8.17e-06	0.000179	CbGpPWpGaD
Repaglinide—SLCO1B1—Metabolism—EP300—urinary bladder cancer	8.1e-06	0.000177	CbGpPWpGaD
Repaglinide—ALB—Hemostasis—HRAS—urinary bladder cancer	7.81e-06	0.000171	CbGpPWpGaD
Repaglinide—CYP2C8—Metabolism—PPARG—urinary bladder cancer	7.11e-06	0.000156	CbGpPWpGaD
Repaglinide—ALB—Metabolism—PPARG—urinary bladder cancer	7.07e-06	0.000155	CbGpPWpGaD
Repaglinide—CYP3A4—Metabolism—NQO1—urinary bladder cancer	6.95e-06	0.000152	CbGpPWpGaD
Repaglinide—CYP2C8—Metabolism—CREBBP—urinary bladder cancer	6.83e-06	0.00015	CbGpPWpGaD
Repaglinide—ALB—Metabolism—CREBBP—urinary bladder cancer	6.79e-06	0.000149	CbGpPWpGaD
Repaglinide—CYP3A4—Metabolism—GSTP1—urinary bladder cancer	5.8e-06	0.000127	CbGpPWpGaD
Repaglinide—CYP2C8—Metabolism—PTGS2—urinary bladder cancer	5.59e-06	0.000122	CbGpPWpGaD
Repaglinide—ALB—Metabolism—PTGS2—urinary bladder cancer	5.56e-06	0.000122	CbGpPWpGaD
Repaglinide—CYP3A4—Metabolism—TYMS—urinary bladder cancer	5.39e-06	0.000118	CbGpPWpGaD
Repaglinide—CYP3A4—Metabolism—NCOR1—urinary bladder cancer	5.33e-06	0.000117	CbGpPWpGaD
Repaglinide—CYP3A4—Metabolism—GSTM1—urinary bladder cancer	5.33e-06	0.000117	CbGpPWpGaD
Repaglinide—CYP3A4—Metabolism—GPX1—urinary bladder cancer	5.1e-06	0.000112	CbGpPWpGaD
Repaglinide—CYP3A4—Metabolism—ERCC2—urinary bladder cancer	5.01e-06	0.00011	CbGpPWpGaD
Repaglinide—CYP2C8—Metabolism—PTEN—urinary bladder cancer	4.88e-06	0.000107	CbGpPWpGaD
Repaglinide—ALB—Metabolism—PTEN—urinary bladder cancer	4.85e-06	0.000106	CbGpPWpGaD
Repaglinide—CYP3A4—Metabolism—MTHFR—urinary bladder cancer	4.71e-06	0.000103	CbGpPWpGaD
Repaglinide—CYP2C8—Metabolism—EP300—urinary bladder cancer	4.65e-06	0.000102	CbGpPWpGaD
Repaglinide—ALB—Metabolism—EP300—urinary bladder cancer	4.63e-06	0.000101	CbGpPWpGaD
Repaglinide—CYP3A4—Metabolism—PPARG—urinary bladder cancer	3.82e-06	8.36e-05	CbGpPWpGaD
Repaglinide—CYP3A4—Metabolism—CREBBP—urinary bladder cancer	3.67e-06	8.03e-05	CbGpPWpGaD
Repaglinide—CYP3A4—Metabolism—PTGS2—urinary bladder cancer	3e-06	6.57e-05	CbGpPWpGaD
Repaglinide—CYP3A4—Metabolism—PTEN—urinary bladder cancer	2.62e-06	5.73e-05	CbGpPWpGaD
Repaglinide—CYP3A4—Metabolism—EP300—urinary bladder cancer	2.5e-06	5.47e-05	CbGpPWpGaD
